We have recently expanded our indications for exparel (liposomal bupivacaine) and have had a few near misses with other products containing local anesthetics within the 96 hour window. In one case a compounded preparation containing ropivacaine was ordered and prepared for a patient who had received exparel pre-op. In another case, an epidural order was placed for a patient with exparel on their profile. We have had several instances of patients receiving lidocaine patches after exparel administration (which the exparel manufacturer does not support.) With so many moving parts, I am wondering what other institutions are doing to prevent these occurrences. Any information or ideas would be greatly appreciated.
Thanks,
Breanne
Breanne Piazik, PharmD, MPH, BCPS
Medication Safety Officer
Elliot Health System
Manchester, NH 03103
603-663-3253